MedTrace Logo

Dopamine and Brain Computer Interface

NCT06729658 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-05-31

No results posted yet for this study

Summary

The use of Brain-Computer Interface system (BCI system) allows for the detection of neurophysiological signals on the surface of the head and provides feedback to subjects or patients. For patients with neurological disorders who have severe motor deficits, self-generated brain signals can be translated, for example, into orthosis-supported movement of the paralyzed limb. Another possibility is to translate the brain signal into peripheral electrostimulation (functional electrical stimulation, FES), which generates muscle contraction and thus movement.

Fundamentally, BCI technology can be used as a replacement therapy when no recovery of motor function is expected. Another important application lies in improving motor training, relearning, and initiating movements. In the latter case, it is hoped that BCI training will stimulate neuroplastic mechanisms that lead to functional improvement.

Problems on the translational path to clinical application are:

* The high interindividual variability between different people regarding learning to control the BCI system;
* The extent of learning and motor improvement is often limited For this reason, the present study aims to investigate whether dopaminergic influence on the brain affects the effectiveness of using a BCI system in healthy subjects.

Conditions

  • Healthy Participants

Interventions

DRUG

Madopar

Experimental group participants will receive Madopar 125mg for 6 days.

DRUG

Placebo

Control group participants will receive placebo for 6 days.

Sponsors & Collaborators

  • Max Planck Institute for Human Cognitive and Brain Sciences

    lead OTHER

Principal Investigators

  • Arno Villringer, PhD · Max Planck Institute for Human Cognitive and Brain Sciences

  • Bernhard Sehm, PhD · Max Planck Institute for Human Cognitive and Brain Sciences

  • Khosrov A. Grigoryan, MSc · Max Planck Institute for Human Cognitive and Brain Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2023-02-27
Completion
2024-08-06

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06729658 on ClinicalTrials.gov